Figure 1. NBP treatment attenuates brain injury after pMCAO. (A) Structure of dl-NBP. Racemic NBP was used in this study. (B) Experimental design. The pMCAO model was established, the rats were grouped, and then the drugs were administered via the tail vein for nine days. (C) The survival of each group. ### P < 0.001 vs. the sham group, * P < 0.05 vs. the pMCAO group in a Log-rank (Mantel-Cox) test. (D) The mNSS of each group. The data are presented as the mean ± SD, n = 5, and were assessed using one-way ANOVA. (E) Representative images of the brain morphology and statistical analysis of the injury area following hematoxylin and eosin staining. The striatum on the lesioned side was scanned at 200× magnification, as shown on the right. Scale bar = 3 mm for the full coronal section; 100 μm for microscopic observation. The injury area was delineated using Motic DSAssistant Lite and analyzed with Image J. ### P < 0.001 vs. the sham group (P = 0.0009, pMCAO vs. Sham), * P < 0.05 vs. the pMCAO group (P =0.0161, NBP vs. pMCAO; P = 0.0488 UK vs. pMCAO) in one-way ANOVA, n = 3.